Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for recurrent vasovagal syncope
IRCT20180125038507N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neurocardiogenic syncope (NCS) comparing Standard treatment plus atomoxetine with Standard treatment plus placebo (2 arms). Primary endpoint: Number of syncopal or presyncopal episodes. Started Jul 2018; status: completed.
02
Drugs
atomoxetine
03
Conditions
Neurocardiogenic syncope (NCS)
Beyond the preview
Go deeper on IRCT20180125038507N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180125038507N1.